HCV Oligomer Assays for Genotype-Reliable Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for detecting and quantifying Hepatitis C Virus (HCV) nucleic acid are complicated by genetic heterogeneity among different genotypes, necessitating a need for sensitive and reliable detection and quantification techniques.
Innovation Solution
The use of specific amplification and capture oligomers, including those with target-hybridizing sequences, to form amplicons and complexes with HCV nucleic acid, followed by detection and quantification, which are designed to work across various HCV genotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nucleic acid detection methods are used, then detection can be performed, but reliability is reduced due to genetic heterogeneity among different HCV genotypes
Solution Approach 1:
The patent designs amplification oligomers with target-hybridizing sequences that can universally bind to conserved regions across multiple HCV genotypes (at least 14 contiguous nucleotides of HCV sequence). This universal binding capability allows a single detection system to reliably detect diverse genotypes without requiring genotype-specific reagents, thereby simultaneously improving reliability and adaptability.
Solution Approach 2:
The patent focuses on targeting specific conserved regions within the HCV genome (positions 5, 7, 12, and 15 of SEQ ID NO: 2) where sequence homology exists across genotypes. By concentrating detection efforts on these locally conserved regions rather than variable regions, the system achieves reliable detection across genotype diversity.
2Measurement precision
If detection sensitivity is increased through specific oligomer design, then detection capability improves, but system complexity increases
Solution Approach 1:
The patent divides the detection system into distinct functional components: capture oligomers for nucleic acid isolation, amplification oligomers with specific target-hybridizing sequences for amplification, and detection mechanisms for amplicon identification. This segmentation allows each component to be optimized for its specific function while maintaining overall system manageability and reducing assay complexity.
Solution Approach 2:
The patent introduces amplification oligomers as intermediary elements that bridge the gap between initial HCV nucleic acid detection and final signal generation. These oligomers with conserved region binding capability serve as mediators that enhance detection sensitivity by amplifying the signal from conserved genomic regions without requiring direct detection of variable regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables sensitive and reliable detection and quantification of HCV nucleic acid, irrespective of genotype, facilitating monitoring and assessing infection severity.
Implementation Method 1
the first amplification oligomer comprises a target-hybridizing sequence comprising at least 10 contiguous nucleotides of SEQ ID NO: 2... the target-hybridizing sequences of the first and second amplification oligomers each comprise at least about 14 contiguous nucleotides of Hepatitis C virus sequence
Implementation Method 2
performing a nucleic acid amplification reaction in the composition which produces one or more amplicons in the presence of a Hepatitis C virus nucleic acid
Data Source
AI summary
This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis C virus (HCV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the 5′ untranslated region of HCV and are configured to provide substantially equivalent quantification of different genotypes and variants of HCV.